Spesolimab Improves Quality of Life in Generalized Pustular Psoriasis (GPP) as Measured by Proportion of Patients With Dermatology Life Quality Index (DLQI) Scores of 0 or 1 and Reduction in Pain Severity Over Time: Results From the EFFISAYIL® 2 Trial. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 9, n. 6, p. s652, 2025. DOI: 10.25251/fmm5fj59. Disponível em: https://skin.dermsquared.com/skin/article/view/3926. Acesso em: 20 apr. 2026.